Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells

Gynecologic Oncology

Volumn 63, Issue 2, 1996, Pages 219-227

  Hamada, Katsuyuki ^a   Sakaue, Morito ^a   Alemany, Ramon ^c   Zhang, Wei Wei ^c   Horio, Yoshitsugu ^a   Roth, Jack A ^a   Mitchell, Michele Follen ^b,d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL TRANSFER; DNA TRANSFECTION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0030298504     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0310     Document Type: Article

References (32)

1. 1. Brinton, L. A. Epidemiology of cervical cancer: Overview, in The epidemiology of human papillomavirus and cervical cancer (N. Munoz, F. Bosch, K. Y. Shah, and A. Meheus, Eds.), Lyon, IARC Sci. Publ. 119, pp. 3-23 (1992).
2. 2. Durst, M., Gissmann, L., Ikenberg, H., and zur Hausen, H. A papillomavirus DNA from cervical carcinomas and its prevalence in cancer biopsy samples from different geographic regions, Proc. Natl. Acad. Sci. USA 80, 3812-3815 (1983).
3. 3. Steele, C., and Shillitoe, E. J. Viruses and oral cancer, Crit. Rev. Oral Biol. Med. 2, 153-175 (1991).
4. 4. Fujita, M., Inoue, M., Tanizawa, O., Iwamoto, S., and Enomoto, T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papilloma infection, Cancer Res. 52, 5323-5328 (1992).
5. 5. Scheffner, M., Huibregtse, M. M., Vierstra, R. D., and Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53, Cell 75, 495-505 (1993).
6. 6. Howley, P. M., Scheffner, M., and Munger, K. Oncoproteins encoded by the cancer-associated human papillomavirus target the products of the retinoblastoma and p53 tumor suppressor genes, Cold Spring Harbor Symp. Quant. Biol. 56, 149-155 (1991).
7. 7. Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., and zur Hausen, H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells, Nature 314, 111-114 (1985).
8. 8. Kaur, P., McDougall, J. K., and Cone, R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames, J. Gen. Virol. 70, 1261-1266 (1989).
9. 9. von Knebel Doeberitz, M., Oltersford, T., Schwarz, E., and Gissmann, L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-I cervical carcinoma cells, Cancer Res. 48, 3780-3786 (1988).
10. 10. Inouye, M. Antisense RNA: Its functions and applications in gene regulation - A review, Gene 72, 25-34 (1988).
11. 11. Steele, C., Sacks, P. G., Adler-Storthz, K., and Shillitoe, E. J. Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18, Cancer Res. 52, 4706-4711 (1992).
12. 12. Steele, C., Cowsert, L. M., and Shillitoe, E. J. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines, Cancer Res. 53, 2330-2337 (1993).
13. 13. Yee, C., Krishnan-Hewlett, I., Baker, C. C., Schlegel, R., and Howley, P. M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines, Am. J. Pathol. 119, 361-366 (1985).
14. 14. Hamada, K., Zhang, W. W., Alemany, R., Roth, J. A., Wolf, J., and Mithcell, M. F. Growth inhibition of human cervical cancer cells with the recombinant adenovirus-p53 in vitro, Gynecol. Oncol. 60, 373-379 (1996).
15. 15. Watanabe, S., Kanda, T., and Yoshiike, K. Growth dependence of human papillomavirus 16 DNA-positive cervical cancer cell lines and human papillomavirus 16-transformed human and rat cells on the viral oncoproteins, Jpn. J. Cancer Res. 84, 1043-1049 (1993).
16. 16. Crook, T., Morgenstern, J. P., Crawford, L., and Banks, L. Continued expression of HPV 16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras, EMBO J. 8, 513-519 (1987).
17. 17. Tan, T. M. C., and Ting, R. C. Y. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes, Cancer Res. 55, 4599-4605 (1995).
18. 18. Schneider-Grädieke, A., and Schwarz, E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes, EMBO J. 5, 228-2292 (1986).
19. 19. Shirasawa, H., Tanzawa, H., Matsunaga, T., and Simizu, B. Quantitative detection of spliced E6-E7 transcripts of human papillomavirus type 16 in cervical premalignant lesions, Virology 184, 795-798 (1991).
20. 20. Dyson, N., Howley, P., Münger, K., and Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product, Science 243, 934-937 (1989).
21. 21. Tan, T. M. C., Gloss, B., Bernard, H-U., and Ting, R. C. Y. Mechanism of translation of the bicistronic mRNA encoding human papillomavirus type 16 E6-E7 genes, J. Gen. Virol. 7, 2663-2670 (1994).
22. 22. Zerfass, k., Schulze, A., Spitkovsky, D., Friedman, V., Henglein, B., and Jansen-Dürr, P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation, J. Virol. 69, 6389-6399 (1995).
23. 1 phase which can be substituted for mutations in p53, Oncogens 11, 653-661 (1995).
24. 24. Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein, Science 269, 529-531 (1995).
25. 25. Chen, Z., Kamath, P., Zhang, S., Weil, M. M., and Shillitoe, E. J. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18, Cancer Gene Ther. 2, 263-271 (1995).
26. 26. Lu, D., Chtterjee, S., Brar, D., and Wong, K. K. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16, Cancer Gene Ther. 1, 267-277 (1994).
27. 27. Lo, K. M. S., Biasolo, A., Dehni, G., Palu, G., and Hasletine, W. A. Inhibition of replication of HIV-1 by retroviral vectors expressing tatantisense and anti-tat ribozyme RNA, Virology 190, 176-183 (1992).
28. 28. Yang, Y., Li, Q., Ertl, H. C. J., and Wilson, J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol. 69, 2004-2015 (1995).
29. 29. Smith, T. A., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., and Kaleko, M. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice, Nat. Genet. 5, 397-402 (1993).
30. 30. Hamada, K., Zhang, W. W., Alemany, R., Roth, J. A., Wolf, J., and Mitchell, M. F. Gene therapy of cervical cancer by adenovirus-mediated p53 gene transfer, J. Cell Biochem. 21A(Suppl.), 421 (1995).
31. 31. Lenner, P., Dillner, J., Wiklund, F., Hallmans, G., and Stendahl, U. Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix, Cancer Immunol. Immunother. 40, 201-205 (1995).
32. 32. Franco, E. L. Prognostic value of human papillomavirus in the survival of cervical cancer patients: An overview of the evidence, Cancer Epidemiol. Biomarkers Prevent. 1, 499-504 (1992).